KIORA PHARMACEUTICALS INC — fact timeline

KIORA PHARMACEUTICALS INC shareholders approved Approval of the amendment of the 2024 Equity Incentive Plan to increase the maximum number of shares authorized for issuance by 1,500,000 shares at the 2026-06-10 meeting.

“The results of the vote were as follows: Votes For Votes Against Votes Abstained Broker Non-Votes 732,106 311,987 1,576 1,320,660”

KIORA PHARMACEUTICALS INC shareholders approved Ratification of the appointment of Haskell & White LLP as the Company’s independent registered public accounting firm for fiscal year 2026 at the 2026-06-10 meeting.

“The results of the vote were as follows: Votes For Votes Against Votes Abstained 2,358,943 5,403 1,983”

KIORA PHARMACEUTICALS INC shareholders approved Approval, on a non-binding advisory basis, of the compensation of the Company’s named executive officers at the 2026-06-10 meeting.

“The results of the vote were as follows: Votes For Votes Against Votes Abstained Broker Non-Votes 1,019,325 21,670 4,674 1,320,660”

KIORA PHARMACEUTICALS INC shareholders approved Election of Lisa Walters-Hoffert, Aron Shapiro, and Praveen Tyle as Class II Directors at the 2026-06-10 meeting.

“The results of the election were as follows: Name Votes For Votes Withheld Broker Non-Votes Lisa Walters-Hoffert 1,037,950 7,719 1,320,660 Aron Shapiro 1,030,543 15,126 1,320,660 Praveen Tyle, Ph.D. 1,029,403 16,266 1,320,660”

KIORA PHARMACEUTICALS INC reported financial results for the first quarter ended March 31, 2026.

“On May 8, 2026, Kiora Pharmaceuticals, Inc. (the “Company”) issued a press release announcing financial results for the quarter ended March 31, 2026 and an update on clinical development progress.”

KIORA PHARMACEUTICALS INC issued Tranche A-2 Common Stock purchase warrants to purchase up to 1,966,182 shares of Common Stock at an exercise price of $1.94 per share of warrant to certain institutional investors for included in the combined purchase price of $2.5430 per Private Placement Share and $2.5429 per Pre-Funded Warrant, with each share or warrant accompanied by fou.

“A-2 Warrants”). The combined purchase price for each Private Placement Share, together with the accompanying four Tranche A-1 Warrants and one Tranche A-2 Warrant, will be $2.5430 and the combined purchase price for each Pre-Funded Warrant, together with the accompanying four Tranche A-1 Warrants and one Tranche A-2 Warrant, will be $2.5429, which price”

KIORA PHARMACEUTICALS INC issued Tranche A-1 Common Stock purchase warrants to purchase up to 7,864,727 shares of Common Stock at an exercise price of $1.94 per share of warrant to certain institutional investors for included in the combined purchase price of $2.5430 per Private Placement Share and $2.5429 per Pre-Funded Warrant, with each share or warrant accompanied by fou.

“A-2 Warrants”). The combined purchase price for each Private Placement Share, together with the accompanying four Tranche A-1 Warrants and one Tranche A-2 Warrant, will be $2.5430 and the combined purchase price for each Pre-Funded Warrant, together with the accompanying four Tranche A-1 Warrants and one Tranche A-2 Warrant, will be $2.5429, which price”

KIORA PHARMACEUTICALS INC issued pre-funded Common Stock purchase warrants to purchase an aggregate of up to 1,527,711 shares of Common Stock at an exercise price of $0.0001 per share of warrant to certain institutional investors for combined purchase price of $2.5429 per Pre-Funded Warrant, together with accompanying four Tranche A-1 Warrants and one Tranche A-2 Warrant.

“On April 3, 2026, Kiora Pharmaceuticals, Inc. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain institutional investors (the “Purchasers”), pursuant to which the Company agreed to issue and sell to the Purchasers, and the Purchasers agreed to purchase from the Company (i) 438,471 shares (the “Private Placement Shares”) of the Company’s Common Stock, par value $0.01 per share (“Common Stock”), (ii) pre-funded Common Stock purchase warrants (the “Pre-Funded Warrants”) to purchase an aggregate of up to 1,527,711 shares of Common Stock at an exercise price of $0.0001 per share, (iii) Tranche A-1 Common Stock purchase warrants to purchase up to 7,864,727 shares of Common Stock at an exercise price of $1.94 per share (“the Tranche A-1 Warrants”), and (iv) Tranche A-2 Common Stock purchase warrants to purchase up to 1,966,182 shares of Common Stock at an exercise price of $1.94 per share (the “Tranche A-2 Warrants”). The combined p”

KIORA PHARMACEUTICALS INC issued 438,471 shares of Common Stock of common stock to certain institutional investors for combined purchase price of $2.5430 per Private Placement Share, together with accompanying four Tranche A-1 Warrants and one Tranche A-2 Warrant.

“On April 3, 2026, Kiora Pharmaceuticals, Inc. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain institutional investors (the “Purchasers”), pursuant to which the Company agreed to issue and sell to the Purchasers, and the Purchasers agreed to purchase from the Company (i) 438,471 shares (the “Private Placement Shares”) of the Company’s Common Stock, par value $0.01 per share (“Common Stock”), (ii) pre-funded Common Stock purchase warrants (the “Pre-Funded Warrants”) to purchase an aggregate of up to 1,527,711 shares of Common Stock at an exercise price of $0.0001 per share, (iii) Tranche A-1 Common Stock purchase warrants to purchase up to 7,864,727 shares of Common Stock at an exercise price of $1.94 per share (“the Tranche A-1 Warrants”), and (iv) Tranche A-2 Common Stock purchase warrants to purchase up to 1,966,182 shares of Common Stock at an exercise price of $1.94 per share (the “Tranche A-2 Warrants”). The combined p”

KIORA PHARMACEUTICALS INC entered into Securities Purchase Agreement with certain institutional investors valued at expected aggregate gross proceeds at closing of approximately $5.0 million and potential future warr (effective 2026-04-03).

“On April 3, 2026, Kiora Pharmaceuticals, Inc. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain institutional investors (the “Purchasers”),”

KIORA PHARMACEUTICALS INC reported the fourth quarter and full year ended December 31, 2025 results: net income The Company reported a net loss of $6.5 million in the fourth quarter of 2025, compared with a net loss of $4.2 million.

“Kiora Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Results; Company Advances Retinal Disease Pipeline with Two Active Phase 2 Clinical Trials”

KIORA PHARMACEUTICALS INC reported the quarter ended March 31, 2024 results: revenue $16.0 million, net income $13.5 million.

“Revenue was $16.0 million for the first quarter of 2024, compared to no revenue in the first quarter of 2023. The revenue comes from collaboration revenue as part of an upfront payment from TOI connected to the strategic development and commercialization partnership. Research and development expenses were $1.5 million, net of $0.2 million in offsetting credits related to expenses for KIO-301 which will be reimbursed by TOI, for the first quarter of 2024, compared to $0.4 million, net of $0.3 million in offsetting tax credits, for the first quarter of 2023. The increase was primarily due to a one-time licensing payment made to the University of California related to a sublicense fee of $0.7 million, and a decrease of $0.3 million in R&D tax credits due to reduced credit-eligible expenses given the KIO-301 expenses are now being reimbursed by TOI. General and administrative expenses were $1.3 million for the first quarter of 2024, compared to $1.3 million for the first quarter of 2023. N”

KIORA PHARMACEUTICALS INC shareholders approved Approval of the Adjournment of the Annual Meeting, If Necessary, to Solicit Additional Proxies at the 2024-05-01 meeting.

“The adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there were not sufficient votes in favor of any of the forgoing proposals at the time of the annual meeting was approved. However, the Company elected not to adjourn the meeting to solicit additional proxies for Proposal 4. The results of the vote were as follows: Votes For Votes Against Votes Abstained Broker Non-Votes 17,206,128 377,890 16,544 2,990,721”

KIORA PHARMACEUTICALS INC shareholders approved Ratification of the Appointment of Haskell & White LLP as the Company's Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2024 at the 2024-05-01 meeting.

“The appointment of Haskell & White LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024 was ratified. There were no broker non-votes on this proposal. The results of the vote were as follows: Votes For Votes Against Votes Abstained 18,896,438 1,622,946 71,899”

KIORA PHARMACEUTICALS INC shareholders approved Approval, on a Non-Binding Advisory Basis, of the Compensation of the Company's Named Executive Officers at the 2024-05-01 meeting.

“The compensation of the Company’s named executive officers as disclosed in the Company’s definitive proxy statement filed with respect to the Annual Meeting was approved on a non-binding basis. The results of the vote were as follows: Votes For Votes Against Votes Abstained Broker Non-Votes 16,291,900 1,224,207 84,455 2,990,721”

KIORA PHARMACEUTICALS INC shareholders approved Approval of the Issuance of up to 49,374,590 Shares of Common Stock Upon the Exercise of Tranche A Warrants and Tranche B Warrants at the 2024-05-01 meeting.

“The issuance, as contemplated by Nasdaq Listing Rule 5635, of up to 49,374,590 shares of Common Stock upon the exercise of Tranche A Warrants and Tranche B Warrants issued in a private placement completed in February 2024 was approved. The results of the vote were as follows: Votes For Votes Against Votes Abstained Broker Non-Votes 16,266,989 1,317,078 16,495 2,990,721”

KIORA PHARMACEUTICALS INC shareholders approved Approval of the Company's 2024 Equity Incentive Plan at the 2024-05-01 meeting.

“The Company’s 2024 Equity Incentive Plan was approved. The results of the vote were as follows: Votes For Votes Against Votes Abstained Broker Non-Votes 16,153,997 1,360,851 85,714 2,990,721”

KIORA PHARMACEUTICALS INC shareholders rejected Approval of an Amendment to Restated Certificate of Incorporation to Adjust Voting Requirements for Certain Future Amendments at the 2024-05-01 meeting.

“An amendment to the Company’s Restated Certificate of Incorporation to adjust voting requirements for certain future amendments was not approved. The results of the vote were as follows: Votes For Votes Against Votes Abstained Broker Non-Votes 16,329,852 1,254,063 16,647 2,990,721”

KIORA PHARMACEUTICALS INC shareholders approved Approval of an Amendment to Restated Certificate of Incorporation to Increase Authorized Shares of Common Stock to 150,000,000 at the 2024-05-01 meeting.

“An amendment to the Company’s Restated Certificate of Incorporation to increase the number of authorized shares of Common Stock to 150,000,000 was approved. The results of the vote were as follows: Votes For Votes Against Votes Abstained Broker Non-Votes 16,088,708 1,506,157 5,697 2,990,721”

KIORA PHARMACEUTICALS INC shareholders approved Approval of an Amendment of Our Restated Certificate of Incorporation to Effect a Reverse Stock Split at the 2024-05-01 meeting.

“An amendment to the Company’s Restated Certificate of Incorporation to effect a Reverse Stock Split of the shares of Common Stock at a ratio of not less than 1-for-2 and not greater than 1-for-10, with the exact ratio of, effective time of and decision to implement the Reverse Stock Split to be determined by the Company’s Board of Directors was approved. The results of the vote were as follows: Votes For Votes Against Votes Abstained 18,297,948 2,258,164 35,171”

KIORA PHARMACEUTICALS INC shareholders approved Election of David Hollander, MD, MBA and Erin Parsons as Class III Directors at the 2024-05-01 meeting.

“David Hollander, MD, MBA and Erin Parsons were elected as Class III Directors for a three-year term, such term to continue until the annual meeting of stockholders in 2027 and until such directors’ successors are duly elected and qualified or until their earlier resignation or removal. Due to the plurality election, votes could only be cast in favor of or withheld from the nominee and thus votes against were not applicable. The results of the election were as follows: Name Votes For Votes Withheld Broker Non-Votes David Hollander, MD, MBA 16,555,192 1,045,370 2,990,721 Erin Parsons 16,478,582 1,121,980 2,990,721”

KIORA PHARMACEUTICALS INC reported financial results for the year ended December 31, 2023.

“Kiora Pharmaceuticals, Inc. (the "Company") issued a press release announcing financial results for the year ended December 31, 2023 and an update on clinical development progress.”

KIORA PHARMACEUTICALS INC entered into Placement Agency Agreement with Maxim Group LLC (effective 2024-01-31).

“On January 31, 2024 and in connection with the Securities Purchase Agreement, the Company entered into a customary placement agency agreement (the “Placement Agency Agreement”) with Maxim Group LLC (“Maxim”).”

KIORA PHARMACEUTICALS INC entered into Securities Purchase Agreement with certain institutional investors valued at approximately $15.0 million (effective 2024-01-31).

“On January 31, 2024, Kiora Pharmaceuticals, Inc. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain institutional investors (the “Purchasers”)”

KIORA PHARMACEUTICALS INC entered into Exclusive License and Development Agreement with Théa Open Innovation SAS valued at up-front payment of $16.0 million (effective 2024-01-25).

“On January 25, 2024, Kiora Pharmaceuticals, Inc. (the “Company”) entered into an Exclusive License and Development Agreement (the “Agreement”) with Théa Open Innovation SAS (“TOI”) with respect to the Company’s KIO-301 molecular photoswitch product (the “Product”).”

KIORA PHARMACEUTICALS INC received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“January 16, 2024, Nasdaq notified the Company in writing (the “Extension Letter”) that while the Company had not regained compliance with the Bid Price Rule, it was eligible for an additional 180-day compliance period, or until July 15, 2024, to regain compliance with the Bid Price Rule. Nasdaq’s determination was based on the Company having met the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on The Nasdaq Capital Market, with the exception of the Bid Price Rule, and on the Company’s written notice to Nasdaq o”

KIORA PHARMACEUTICALS INC shareholders approved Approval of the issuance of more than 20% of the Company’s issued and outstanding common stock pursuant to the purchase agreement with Lincoln Park Capital Fund, LLC at the 2023-09-27 meeting.

“Proposal 2 - Approval of the Issuance of More Than 20% of the Company’s Issued and Outstanding Common Stock Pursuant to the Company’s Purchase Agreement with Lincoln Park The approval, for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of more than 20% of the Company’s issued and outstanding common stock pursuant to the Company’s purchase agreement with Lincoln Park Capital Fund, LLC, was approved. The results of the vote were as follows: Votes For Votes Against Votes Abstained 2,051,285 432,684 264,409”

KIORA PHARMACEUTICALS INC shareholders approved Approval of an amendment to the 2014 Equity Incentive Plan to increase the maximum number of shares authorized for issuance by 1,000,000 shares and to revise the evergreen provision at the 2023-09-27 meeting.

“Proposal 1 – Approval of Equity Incentive Plan Amendment The amendment to the Company’s 2014 Equity Incentive Plan to increase the maximum number of shares authorized for issuance thereunder by 1,000,000 shares and to revise the provision governing the maximum shares issuable under the evergreen provision was approved. The results of the election were as follows: Voted For Votes Against Votes Abstained 1,872,064 612,104 264,210”

Praveen Tyle was appointed as Chairman at KIORA PHARMACEUTICALS INC.

“the Board appointed Praveen Tyle, Ph.D. as Chairman of the Board.”

Paul Chaney resigned as Chairman at KIORA PHARMACEUTICALS INC.

“On September 20, 2023 (the “Effective Date”), Paul Chaney resigned as Chairman and member of the Board of Directors (the “Board”) of Kiora Pharmaceuticals, Inc. (the “Company”) from the Audit Committee and Nominating and Corporate Governance Committee of the Board, effective as of the Effective Date.”

KIORA PHARMACEUTICALS INC reported second quarter 2023 results: net income Net loss was $2.6 million for the second quarter of 2023.

“On August 8, 2023, Kiora Pharmaceuticals, Inc. (the “Company”) issued a press release announcing financial results for the first quarter ended June 30, 2023 and an update on clinical development progress.”

Carmine Stengone was appointed as Director at KIORA PHARMACEUTICALS INC.

“On August 1, 2023, the Board of Directors (the “Board”) of Kiora Pharmaceuticals, Inc. (the “Company”) appointed Carmine Stengone as a member of the Board.”

KIORA PHARMACEUTICALS INC received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“July 18, 2023, Kiora Pharmaceuticals, Inc. (the “Company”) received a deficiency letter (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the bid price for the Company’s common stock had closed below $1.00 per share, which is the minimum closing price required to maintain continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Requirement”). The Notice has no immediate effect on the listing of the Company’s common”

KIORA PHARMACEUTICALS INC shareholders approved Ratification of the Appointment of Haskell & White LLP as the Company’s independent registered public accounting firm at the 2023-06-21 meeting.

“The appointment of Haskell & White LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 was ratified. There were no broker non-votes on this proposal. The results of the vote were as follows: Votes For Votes Against Votes Abstained 798,689 14,659 19,738”

KIORA PHARMACEUTICALS INC shareholders approved Approval, on a Non-Binding Basis, of the Compensation of the Company’s Executive Officers at the 2023-06-21 meeting.

“The compensation of the Company’s executive officers as disclosed in the Company’s definitive proxy statement filed with respect to the Annual Meeting was approved on a non-binding basis. The results of the vote were as follows: Votes For Votes Against Votes Abstained Broker Non-Votes 243,595 43,492 8,996 537,003”

KIORA PHARMACEUTICALS INC shareholders approved Election of Kenneth Gayron, Aron Shapiro and Praveen Tyle, Ph.D. as Class II Directors at the 2023-06-21 meeting.

“Kenneth Gayron, Aron Shapiro and Praveen Tyle, Ph.D. were elected as Class II Directors for a three-year term, such term to continue until the annual meeting of stockholders in 2026 and until such directors’ successors are duly elected and qualified or until their earlier resignation or removal. Due to the plurality election, votes could only be cast in favor of or withheld from the nominee and thus votes against were not applicable. The results of the election were as follows: Name Votes For Votes Withheld Broker Non-Votes Kenneth Gayron 271,239 24,844 537,003 Aaron Shapiro 266,275 29,808 537,003 Praveen Tyle, Ph.D. 264,242 31,841 537,003”

KIORA PHARMACEUTICALS INC entered into Underwriting Agreement with Ladenburg Thalmann & Co. Inc. valued at Underwriting Agreement for public offering of common stock, preferred stock, and warrants, net proce (effective 2023-06-02).

“On June 2, 2023, Kiora Pharmaceuticals, Inc. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with Ladenburg Thalmann & Co. Inc., as underwriter (the “Underwriter”), pursuant to which the Company agreed to issue and sell, in a firm commitment underwritten public offering by the Company (the “Public Offering”), (i) 1,447,628 shares of common stock (the “Common Shares”), (ii) 3,908 shares of Series F Convertible Preferred Stock (the “Preferred Shares”) convertible into up to 3,552,372 shares of common stock, (iii) Class C Warrants (the “Class C Warrants”) to purchase up to 5,000,000 shares of common stock, and (iv) Class D Warrants (the “Class D Warrants” and, together with the Class C Warrants, the “Warrants”) to purchase up to 5,000,000 shares of common stock, priced at a public offering price of $1.10 per Common Share, Class C Warrant and Class D Warrant or $999.90 per Preferred Share, 909 Class C Warrants and 909 Class D Warrants.”

KIORA PHARMACEUTICALS INC reported first quarter ended March 31, 2023 results: net income $1.9 million.

“Net loss was $1.9 million for the first quarter of 2023 compared to $3.6 million for the first quarter of 2022.”

KIORA PHARMACEUTICALS INC engaged Haskell & White LLP as its auditor.

“the Audit Committee has appointed Haskell & White LLP as the Company’s independent registered public accounting firm, effective March 24, 2023”

KIORA PHARMACEUTICALS INC dismissed EisnerAmper LLP as its auditor.

“the Audit Committee dismissed EisnerAmper as the Company’s independent registered public accounting firm as of the Effective Date”

KIORA PHARMACEUTICALS INC reported financial results for the fiscal year and fourth quarter ended December 31, 2022.

“On March 23, 2023, Kiora Pharmaceuticals, Inc. (the “Company”) issued a press release announcing financial results for the fiscal year and fourth quarter ended December 31, 2022 and an update on clinical development progress.”

KIORA PHARMACEUTICALS INC entered into Purchase Agreement with Lincoln Park Capital Fund, LLC valued at $10.0 million (effective 2023-02-03).

“On February 3, 2023, the Company entered into a purchase agreement (the “Purchase Agreement”) and a registration rights agreement (the “Registration Rights Agreement”), with Lincoln Park, pursuant to which Lincoln Park has committed to purchase up to $10.0 million of Common Stock (subject to certain limitations), from time to time and at the Company’s sole discretion over the term of the Purchase Agreement.”

KIORA PHARMACEUTICALS INC entered into Securities Purchase Agreement with Lincoln Park Capital Fund, LLC valued at $200,000.00 (effective 2023-02-02).

“On February 2, 2023, Kiora Pharmaceuticals, Inc. (the “Company”), entered into a securities purchase agreement (the “Securities Purchase Agreement”), with Lincoln Park Capital Fund, LLC (“Lincoln Park”), pursuant to which the Company agreed to issue and sell to Lincoln Park, and Lincoln Park agreed to purchase from the Company (i) 52,798 shares (the “Private Placement Shares”) of the Company’s Common Stock, par value $0.01 per share (“Common Stock”) and (ii) warrants (the “Warrants”) to initially purchase an aggregate of up to 105,596 shares of Common Stock (the “Warrant Shares”), at an exercise price of $3.538 per share. The combined purchase price for each Private Placement Share and two Warrants is $3.788, which price represents the “Minimum Price” in accordance with Nasdaq Listing Rule 5635(d), for expected aggregate gross proceeds of $200,000.00.”

KIORA PHARMACEUTICALS INC entered into Inducement Letters with holders of the Prior Warrants (Exercising Holders) valued at approximately $3.12 million (effective 2022-11-17).

“On November 17, 2022, the Company entered into warrant exercise inducement offer letters (“Inducement Letters”) with holders of the Prior Warrants (collectively, the “Exercising Holders”) pursuant to which the holders agreed to exercise for cash all of their Class A Warrants to purchase 654,609 shares of the Company’s common stock in exchange for the Company’s agreement to issue new warrants (the “Inducement Warrants”) on substantially the same terms as the Existing Warrants, except as set forth herein, to purchase up to 654,609 shares of the Company’s common stock. The Company expects to receive aggregate gross proceeds of approximately $3.12 million from the exercise of the Existing Warrants by the Exercising Holders and the sale of the Inducement Warrants.”

Melissa Tosca was appointed as Executive Vice President of Finance at KIORA PHARMACEUTICALS INC.

“On September 13, 2022 (the “Effective Date”), Kiora Pharmaceuticals Inc. (the “Company”) appointed Melissa Tosca as Executive Vice President of Finance of the Company, effective as of the Effective Date.”

Brian M. Strem, Ph.D. changed role as principal financial and accounting officer at KIORA PHARMACEUTICALS INC.

“Brian M. Strem, Ph.D., the Company’s President and Chief Executive Officer, will assume the role of the Company’s principal financial and accounting officer.”

Susan L. Drexler resigned as Interim Chief Financial Officer at KIORA PHARMACEUTICALS INC.

“Effective as of June 16, 2022, Ms. Drexler resigned as Interim Chief Financial Officer of the Company”

Susan L. Drexler was appointed as Interim Chief Financial Officer at KIORA PHARMACEUTICALS INC.

“On April 21, 2022 (the “Effective Date”), the Board of Directors of Kiora Pharmaceuticals Inc. (the “Company”) appointed Susan L. Drexler as Interim Chief Financial Officer of the Company, effective as of the Effective Date.”

Brian M. Strem was appointed as President and Chief Executive Officer at KIORA PHARMACEUTICALS INC.

“Effective as of March 18, 2022, Brian M. Strem, Ph.D., the Company’s President and Chief Executive Officer, was appointed as the Company’s principal financial officer and principal accounting officer.”

Michael Meluzio resigned as Corporate Controller at KIORA PHARMACEUTICALS INC.

“On March 18, 2022, Michael Meluzio resigned as the Corporate Controller of Kiora Pharmaceuticals, Inc. (the “Company”) to pursue other opportunities.”